Show simple item record

dc.contributor.authorHeneghan, Carl
dc.date.accessioned2019-07-17T09:22:34Z
dc.date.available2019-07-17T09:22:34Z
dc.date.issued2019-06
dc.identifier.citationColm D. Andrews; Russell G. Foster; Iona Alexander; Sridhar Vasudevan; Susan M. Downes; Carl Heneghan; Annette Plüddemann .Sleep–Wake Disturbance Related to Ocular Disease: A Systematic Review of Phase-Shifting Pharmaceutical Therapies. TVST May 2019 Volume 8, Issue 3en
dc.identifier.issn2164-2591
dc.identifier.urihttps://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/275
dc.descriptionAvailable at: https://tvst.arvojournals.org/article.aspx?articleid=2737083 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.en
dc.description.abstractPurpose: Light input, via the eyes, is essential for regulating circadian rhythms. Eye diseases can cause disruption of vital biological rhythms. Of totally blind people, 87% report sleep problems. There are no UK guidelines for visual disturbance–related circadian rhythm disruption. Our objective was to systematically review the literature to determine the effectiveness of pharmacological agents on the sleep quality of patients with sleep disturbance related to ocular disease. Methods: We searched CENTRAL, MEDLINE, EMBASE, PsycINFO, and CINAHL alongside protocol registries and citation searches. We assessed the risk of bias using the Cochrane Risk of Bias Assessment Tool and assessed the strength of overall evidence using GRADE criteria. Results: Four studies (n=116) met the inclusion criteria. Low-quality evidence showed that melatonin can cause entrainment (1 study), increases in total sleep time (all 3 studies), and reduction in sleep latency (1 study). Low-to-moderate quality evidence showed tasimelteon causes a significant improvement in entrainment, midpoint of sleep timing, lower-quartile of night-time sleep, and upper-quartile of daytime sleep. Conclusions: Results should be treated with caution as the melatonin studies had risks of bias due to inadequate reporting of randomization and masking procedures. The tasimelteon trial had a risk of reporting bias due to changing the outcomes after enrolling participants. Despite the paucity of trials, melatonin and tasimelteon may cause entrainment and improve subjective sleep measures with limited side effects. Translational Relevance: Given the relative cost melatonin may be a viable choice for treatment of circadian rhythm sleep disorders in the blind and warrants further research.en
dc.description.sponsorshipSupported by the NIHRen
dc.description.urihttps://doi.org/10.1167/tvst.8.3.49
dc.language.isoenen
dc.subjectSleepen
dc.subjectEye Diseasesen
dc.titleSleep–Wake Disturbance Related to Ocular Disease: A Systematic Review of Phase-Shifting Pharmaceutical Therapiesen
dc.typeArticleen


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record